<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810195</url>
  </required_header>
  <id_info>
    <org_study_id>HKN AR01</org_study_id>
    <nct_id>NCT04810195</nct_id>
  </id_info>
  <brief_title>Early neo2 Registry of the Acurate neo2 TAVI Prosthesis</brief_title>
  <official_title>Early neo2 Registry of the Acurate neo2 TAVI Prosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andreas R端ck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Early neo2 registry will study up to 500 patients treated with the updated Boston Acurate&#xD;
      neo2 TAVI prosthesis at various European hospitals. The data is gathered from routine&#xD;
      healthcare and there are no study-mandated additional procedures. The main endpoint is a&#xD;
      combined efficiency and safety endpoint after 30 days. Imaging data (echocardiography,&#xD;
      computed tomography and aortography) will be analysed centrally by a core lab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale The Boston Scientific Acurate neo2 TAVI prosthesis was launched&#xD;
      commercially in Europe in September 2020 as a successor to the original Acurate neo&#xD;
      prosthesis. Modifications include an added sealing skirt. The original Acurate neo failed to&#xD;
      reach non-inferiority to other TAVI prostheses in two randomized trials. There is a need to&#xD;
      gather initial safety and efficacy data from this next generation prosthesis, as there is no&#xD;
      larger dataset presented after the CE-mark study of the Acurate neo2.&#xD;
&#xD;
      Project objectives To gather initial safety and efficacy data in the initial up to 500&#xD;
      consecutive patients treated with the Acurate neo2 in various European sites.&#xD;
&#xD;
      Karolinska will be the coordinating center for data collection.&#xD;
&#xD;
      Methods Data will be collected in an anonymous form and sent to Karolinska for compilation&#xD;
      and statistics. Data collection will continue until 500 patients are reached (April, 2021).&#xD;
&#xD;
      Statistics Standard descriptive statistics will be used for the main results. For the&#xD;
      comparison to SCOPE data (with the original Acurate neo prosthesis) on postoperative aortic&#xD;
      insufficiency, standard statistical methods will used (Fishers exact test for categorical&#xD;
      variables, and t-test for continuous measurements such as amount of regurgitation by&#xD;
      videodensitometry).&#xD;
&#xD;
      Core lab studies The core lab analyses will be performed at CORRIB in Galway (Prof. Serruys&#xD;
      et al).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>30 days</time_frame>
    <description>any of&#xD;
Postoperative aortic insuffiency moderate or higher (in hospital echo, site reported)&#xD;
Postoperative new permanent pacemaker (in hospital)&#xD;
30 days mortality&#xD;
30 days stroke&#xD;
Acute Kidney Injury (AKIN grade 3) (in hospital)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Postoperative aortic insufficiency more than mild by transthoracic echo</measure>
    <time_frame>Within 7 days of procedure</time_frame>
    <description>Core-lab analysis of the postoperative transthoracic echo for aortic insufficiency: percentage of patients with more than mild insufficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Postoperative aortic insufficiency more than mild by aortography</measure>
    <time_frame>Same day as procedure</time_frame>
    <description>Core-lab analysis of the aortogram in the end of the procedure for quantification of aortic insufficiency (videodensitometry): rate of patients with more than mild insuffiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative aortic valve gradients</measure>
    <time_frame>Within 7 days of procedure</time_frame>
    <description>Aortic prosthesis mean gradient (mmHg) on postoperative transthoracic echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major acute procedural complications</measure>
    <time_frame>Same day as procedure</time_frame>
    <description>Intraprocedural complications such as valve embolization, need for second valve, anular rupture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural contrast use</measure>
    <time_frame>Same day as procedure</time_frame>
    <description>The average amount of contrast in ml per procedure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Boston Scientific Acurate neo2 TAVR device</intervention_name>
    <description>The newest generation of the Acurate neo2 TAVR device, launched in Europe in 2020.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The first 500 consecutive patients treated with the Acurate neo2 from up to 15 European&#xD;
        sites which have started using the Acurate neo2.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  that a Acurate neo2 prosthesis has been inserted into the sheath (i.e. a procedure has&#xD;
             been started).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas R端ck, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas R端ck, MD PhD</last_name>
    <phone>+46 8 517771728</phone>
    <email>andreas.ruck@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Meduri, MD</last_name>
    <phone>+46 8 517771728</phone>
    <email>chrismeduri@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Ole De Backer, PhD</last_name>
      <email>ole.debacker@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Won-Keun Kim, MD</last_name>
      <email>w.kim@kerckhoff-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Henrik Bjursten, PhD</last_name>
      <email>henrik.bjursten@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Andreas R端ck</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

